Structure-Activity Relationship Study of Benzamides as Mycobacterium tuberculosis QcrB Inhibitors

Area of Science:

• Medicinal Chemistry
• Organic Chemistry
• Microbiology

Background:

• Morpholinobenzamide derivatives previously showed potent activity against Mycobacterium tuberculosis.
• The morpholine group in these compounds is metabolically labile, posing a challenge for drug development.

Purpose of the Study:

• To conduct structure-activity relationship (SAR) studies to identify novel benzamide analogs.
• To replace the metabolically labile morpholine group while maintaining or improving antibacterial activity against Mycobacterium tuberculosis.

Main Methods:

• Synthesis of novel benzamide analogs with modifications at the C-5 position.
• Evaluation of antibacterial activity using IC90 values against Mycobacterium tuberculosis.
• Assessment of cytotoxicity using HepG2 cell lines and CC50 values.
• Determination of metabolic stability using human liver microsomes.

Main Results:

• Identified potent benzamide compounds 16 and 22f with IC90 values of 0.13 μM and 0.09 μM, respectively.
• These analogs feature thiophene and methyl substituents replacing the morpholine group.
• Compounds 16 and 22f exhibited high selectivity indices (300 and 278) and low cytotoxicity (HepG2 CC50 of 39 and 25 μM).
• Compound 16 demonstrated favorable metabolic stability in human liver microsomes.

Conclusions:

• Novel benzamide analogs with modified C-5 substituents are potent against Mycobacterium tuberculosis.
• These compounds offer improved metabolic stability and low cytotoxicity compared to previous series.
• The identified compounds represent promising candidates for further development as anti-tuberculosis agents.